Aliskiren, the first direct renin inhibitor: assessing a role in pediatric hypertension and kidney diseases

Shahid Nadeem, Donald L. Batisky

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

This article provides a review of the role of aliskiren, a direct renin inhibitor, in pediatric hypertension and kidney diseases. Among the many mechanisms involved in regulating blood pressure, the renin–angiotensin–aldosterone system (RAAS) plays a major role. Additionally, the RAAS has been identified as a contributing factor to cardiovascular and renal diseases for more than three decades. The potential benefits of inhibiting the RAAS by aliskiren alone or in combination with other RAAS blockers (ACEIs, ARBs) seem to be theoretically promising. However, caution should be exercised in treating children, especially in those with significant chronic kidney disease until there is more evidence regarding the safety and efficacy of this new drug in the pediatric population from ongoing clinical trials.

Original languageEnglish (US)
Pages (from-to)2105-2111
Number of pages7
JournalPediatric Nephrology
Volume29
Issue number11
DOIs
StatePublished - Nov 2014
Externally publishedYes

Keywords

  • Aliskiren
  • Angiotensin
  • Blood pressure
  • Hyperkalemia
  • Hypertension
  • Renin

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Nephrology

Fingerprint

Dive into the research topics of 'Aliskiren, the first direct renin inhibitor: assessing a role in pediatric hypertension and kidney diseases'. Together they form a unique fingerprint.

Cite this